MedTrace Logo

Effect of BI 1181181 on Midazolam, Warfarin, Omeprazole and Digoxin

NCT02345304 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2015-03-10

No results posted yet for this study

Summary

To assess the influence of different dose strengths of BI 1181181 on single dose kinetics of midazolam (CYP3A4 probe drug), warfarin (CYP2C9 probe drug), omeprazole (CYP2C19 probe drug) and digoxin (P-gp probe drug)

Conditions

  • Healthy

Interventions

DRUG

Omeprazole

DRUG

Warfarin

DRUG

BI 1181181

DRUG

Midazolam

DRUG

Omeprazole

DRUG

BI 1181181

DRUG

Midazolam

DRUG

Midazolam

DRUG

Warfarin

DRUG

BI 1181181

DRUG

Digoxin

DRUG

Digoxin

Sponsors & Collaborators

Principal Investigators

  • Boehringer Ingelheim · Boehringer Ingelheim

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-03-31
Primary Completion
2015-04-30
Completion
2015-05-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02345304 on ClinicalTrials.gov